加载中
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
前收盘价
US$4.84
−US$0.14 · -2.81%
盘中时间采用ET。市场数据可能有所延迟。
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
日内区间
当前US$4.84
52周区间
当前US$4.84
盘中时间采用ET。市场数据可能有所延迟。
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
日内区间
当前US$4.84
52周区间
当前US$4.84
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 5942.5万 USD | 5694.4万 USD | 5015.5万 USD | 5387万 USD | 4910.9万 USD |
| 销货成本 | 3090万 USD | 2838.9万 USD | 2940.1万 USD | 2953.2万 USD | 2363.2万 USD |
| 毛利 | 2852.5万 USD | 2855.5万 USD | 2075.4万 USD | 2433.8万 USD | 2547.7万 USD |
| 研究与开发 | 908.4万 USD | 682.5万 USD | 954.4万 USD | 1154.5万 USD | 937.4万 USD |
| 销售、一般及管理费用 | 2047万 USD | 1688.4万 USD | 1813.1万 USD | 1724.2万 USD | 1549.6万 USD |
| 营业费用 | 2966.5万 USD | 2370.9万 USD | 2767.5万 USD | 2878.7万 USD | 2487万 USD |
| 折旧和摊销 | 137.7万 USD | 164万 USD | 186.7万 USD | 224.6万 USD | 162.7万 USD |
| 营业利润 | −114万 USD | 484.6万 USD | −692.1万 USD | −444.9万 USD | 60.7万 USD |
| 净利润 | −117.5万 USD | 470.1万 USD | −727.6万 USD | −533.5万 USD | 54.8万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.00
上涨空间 147.93%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2015年8月12日 | 1:12 | — | — |
已生效 2015年8月12日
1:12
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
